BTAI
BioXcel Therapeutics Inc
NASDAQ: BTAI · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$1.04
-1.89% today
Updated 2026-04-29
Market cap
$28.70M
P/E ratio
—
P/S ratio
44.70x
EPS (TTM)
$-5.73
Dividend yield
—
52W range
$1 – $8
Volume
1.8M
BioXcel Therapeutics Inc (BTAI) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
4 of 8
Last 8 quarters
Avg EPS surprise
-102.8%
Last 4 quarters
Revenue YoY growth
-30.1%
Most recent quarter
EPS YoY growth
+71.2%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-16.0%
Last 2 reports
Positive reaction rate
0%
0 of 2 quarters
Largest single-day move
-20.3%
2025-11-12
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-03-27 | $-1.03 | -61.8% | $1.37 | $1.21 | -11.7% |
| 2025-11-12 | $-2.18 | -2322.2% | $2.02 | $1.61 | -20.3% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $-0.64 | $-1.03 | -61.8% | $256000.00 | -30.1% |
| 2025-09-30 | $-0.09 | $-2.18 | -2322.2% | $98000.00 | -54.2% |
| 2025-06-30 | $-0.13 | $-2.45 | -1784.6% | $120000.00 | -89.1% |
| 2025-03-31 | $-3.04 | $-1.50 | +50.7% | $168000.00 | -71.1% |
| 2024-12-31 | $-5.14 | $-3.56 | +30.7% | $366000.00 | -2.7% |
| 2024-09-30 | $-0.54 | $-0.32 | +40.7% | $214000.00 | -37.2% |
| 2024-06-30 | $-0.71 | $-0.21 | +70.4% | $1.10M | +141.6% |
| 2024-03-31 | $-0.70 | $-0.87 | -24.3% | $582000.00 | +182.5% |
| 2023-12-31 | $-0.91 | $-0.76 | +16.5% | $376000.00 | — |
| 2023-09-30 | $-1.30 | $-1.72 | -32.3% | $341000.00 | — |
| 2023-06-30 | $-1.75 | $-1.83 | -4.6% | $457000.00 | — |
| 2023-03-31 | $-1.62 | $-1.84 | -13.6% | $206000.00 | — |
Frequently asked questions
Has BioXcel Therapeutics Inc beaten earnings estimates?
BioXcel Therapeutics Inc has beaten Wall Street EPS estimates in 4 of its last 8 quarterly reports, with an average EPS surprise of -102.8% over the last 4 quarters.
How does BTAI stock react to earnings?
BTAI stock has moved an average of -16.0% in the trading day following earnings over its last 2 reports, with positive reactions in 0% of those quarters.
What is BioXcel Therapeutics Inc's revenue growth rate?
BioXcel Therapeutics Inc reported year-over-year revenue growth of -30.1% in its most recent quarter, with EPS growing +71.2% year-over-year.